Coya Therapeutics, Inc. (COYA) Thursday reported positive interim results from an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD).
In the study, patients received CTLA4-Ig, followed by a low-dose IL-2 every four weeks, for a total of 22 weeks of dosing and follow-up. Data from the first 5 patients with mild to moderate FTD showed a rapid and durable statistically significant increase in the number and suppressive function of regulatory T cells (Tregs), that play a crucial role in regulating the immune system, compared to baseline values.
Patients with FTD demonstrated minimal to no cognitive decline throughout the study period. Treatment was well tolerated, and no serious adverse events were reported.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.